An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced new preclinical results for its lead program, STAR-0215, aimed at treating hereditary angioedema (HAE). These results will be presented at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting in New Orleans on November 5, 2021, by Chief Scientific Officer Andrew Nichols. STAR-0215 is a monoclonal antibody plasma kallikrein inhibitor still in preclinical development.
Positive
Presentation of new preclinical results for STAR-0215 at a major scientific meeting.
STAR-0215 aims to address the unmet needs in treating hereditary angioedema.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share new preclinical results for STAR-0215 in a presentation titled “STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for the Potential Treatment of HAE” at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting in New Orleans, Louisiana.
The poster will be presented in-person by Andrew Nichols, Ph.D., Chief Scientific Officer at Astria Therapeutics, on Friday, November 5, 2021 at 4:15pm CT, and will be available to all registrants through the ACAAI Meeting website and mobile app.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
What are the preclinical results for STAR-0215 presented by Astria Therapeutics?
Astria Therapeutics announced new preclinical results for STAR-0215, a monoclonal antibody for hereditary angioedema, to be presented at the 2021 ACAAI meeting.
When and where is the presentation of STAR-0215 results happening?
The presentation is on November 5, 2021, at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting in New Orleans.
What is STAR-0215 developed by Astria Therapeutics?
STAR-0215 is a monoclonal antibody plasma kallikrein inhibitor being developed for the treatment of hereditary angioedema.
Who will present the STAR-0215 results at the ACAAI meeting?
Andrew Nichols, Ph.D., the Chief Scientific Officer of Astria Therapeutics, will present the results.
How does STAR-0215 aim to help patients with hereditary angioedema?
STAR-0215 is designed to provide a long-acting treatment option for patients suffering from hereditary angioedema.
